Ronald T. Nixon - 04 Jun 2026 Form 4 Insider Report for Sanara MedTech Inc. (SMTI)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: SMTI
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 20:31:17 UTC
Prior SEC filing: 27 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Ronald T. Nixon

Key filing fact

Ronald T. Nixon filed Form 4 for Sanara MedTech Inc. (SMTI) on 05 Jun 2026.

Key facts

This page summarizes Ronald T. Nixon's Form 4 filing for Sanara MedTech Inc. (SMTI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 20:31.

Change

Previous filing in this sequence was filed on 27 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001322573 Primary reporting owner

Nixon Ronald T

Relationship: Director, 10%+ Owner
Address: 1200 SUMMIT AVE, SUITE 414, FORT WORTH
Signature: /s/ Ronald T. Nixon
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SMTI transaction

Common Stock

Award

Transaction value
Shares: +4,154
Change %: +6.5%
Price: $0.000000^*
Shares after: 68,196
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

SMTI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,452,731
Date: 04 Jun 2026
Ownership: See Footnote
Footnotes: F2

SMTI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 963,856
Date: 04 Jun 2026
Ownership: See Footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.

Footnote F2

Represents shares of the Issuer's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.

Footnote F3

Represents shares of the Issuer's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.